LEXARIA BIOSCIENCE CORP. Increase (Decrease) in Long-term Receivables, Current
LEXARIA BIOSCIENCE CORP. (LEXX) reported Increase (Decrease) in Long-term Receivables, Current of $1 for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for the quarter ending 2026-05-31 was $1.00.
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for the quarter ending 2026-02-28 was $0.00.
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for the quarter ending 2025-11-30 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for the quarter ending 2025-08-31 was -$1.00.
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for fiscal 2025 was $438.00, a 97.08% decline from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. increase (decrease) in long-term receivables, current for fiscal 2024 was $15.02K.
| Period end | Increase (Decrease) in Long-term Receivables, Current 3 month | Increase (Decrease) in Long-term Receivables, Current 6 month | Increase (Decrease) in Long-term Receivables, Current 9 month | Increase (Decrease) in Long-term Receivables, Current 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $1.00 derived: sum of 2 quarters · filed 2026-07-13 | $1.00 10-Q · filed 2026-07-13 | $0.00 derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $0.00 10-Q · filed 2026-04-13 | -$1.00 derived: sum of 3 quarters · filed 2026-04-13 | -$1.00 derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | $0.00 10-Q · filed 2026-01-13 | -$1.00 derived: sum of 2 quarters · filed 2026-01-13 | -$1.00 derived: sum of 3 quarters · filed 2026-07-13 | -$1.00 derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | -$1.00 derived: sum of 2 quarters · filed 2026-07-13 | -$1.00 derived: sum of 3 quarters · filed 2026-07-13 | $438.00 10-K · filed 2025-11-28 |
| 2025-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $0.00 derived: sum of 2 quarters · filed 2026-07-13 | $439.00 10-Q · filed 2026-07-13 | $439.00 derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $439.00 10-Q · filed 2026-04-13 | $439.00 derived: sum of 3 quarters · filed 2026-04-13 | $24.52K derived: sum of 4 quarters · filed 2026-04-13 |
| 2024-11-30 | $439.00 10-Q · filed 2026-01-13 | $439.00 derived: sum of 2 quarters · filed 2026-01-13 | $24.52K derived: sum of 3 quarters · filed 2026-01-13 | |
| 2024-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $24.08K derived: sum of 2 quarters · filed 2025-11-28 | $15.02K 10-K · filed 2025-11-28 | |
| 2024-05-31 | $24.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | $15.02K 10-Q · filed 2025-07-14 | ||
| 2024-02-29 | -$9.06K 10-Q · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |